The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention
| Autor: | Trio Study Team, Rachel Weinrib, Ariane van der Straten, Alexandra Minnis, Jill L. Schwartz, Erica N Browne, Fredrick Owino, Kawango Agot, Kgahlisho Manenzhe, Khatija Ahmed |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Adolescent HIV prevention Population HIV Infections Logistic regression Placebo Condoms Young Adult 03 medical and health sciences 0302 clinical medicine Pregnancy Humans Medicine 030212 general & internal medicine end‐user research HIV and pregnancy Adverse effect education Research Articles multipurpose prevention technologies education.field_of_study 030219 obstetrics & reproductive medicine business.industry Public Health Environmental and Occupational Health Contraceptive Devices Female Odds ratio Kenya Vaginal ring Confidence interval Contraception Infectious Diseases Africa product preference Female business Research Article Demography |
| Zdroj: | Journal of the International AIDS Society |
| ISSN: | 1758-2652 |
| Popis: | Introduction Preventing HIV and unintended pregnancies are key global health priorities. To inform product rollout and to understand attributes of future multipurpose prevention technologies (MPT) associated with preference and use, we evaluated three placebo delivery forms: daily oral tablets, a monthly vaginal ring, and two monthly intramuscular injections in TRIO, a five‐month study among young Kenyan and South African women. Methods HIV‐negative, sexually active, non‐pregnant women aged 18 to 30 were enrolled and randomized to use each placebo delivery form for one month (stage 1). Then, participants chose one product to use for two additional months (stage 2). We assessed safety, product ranking, choice, and use. We examined demographic and behavioural correlates of choice and, reciprocally, unwillingness to use in the future with logistic regression models. Results 277 women enrolled, 249 completed stage 1 and 246 completed stage 2. Median age was 23 years, 49% were Kenyan and 51% were South African. Three participants became pregnant during the study and one participant HIV‐seroconverted. There were 18 product‐related adverse events, six tablets‐related, 11 ring‐related, and one injection‐related. After trying each product, 85% preferred a TRIO product over condoms. Injections were chosen most (64%, 95% confidence interval (CI) 58%, 70%; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|